Standout Papers
- Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study (2023)
- Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial (2016)
Immediate Impact
2 from Science/Nature 56 standout
Citing Papers
Bimetallic Single-Atom Nanozyme-Based Electrochemical-Photothermal Dual-Function Portable Immunoassay with Smartphone Imaging
2024 Standout
Ultralight crystalline hybrid composite material for highly efficient sequestration of radioiodine
2024 Standout
Works of Amy Qin being referenced
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
2023 Standout
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
2016 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Amy Qin | 453 | 465 | 93 | 129 | 12 | 681 | |
| S. Ferrari | 342 | 654 | 124 | 186 | 8 | 842 | |
| Douglas Adkins | 353 | 383 | 74 | 119 | 18 | 638 | |
| Ashwin Shahir | 393 | 465 | 63 | 169 | 26 | 651 | |
| Joseph M. Quagliana | 339 | 403 | 98 | 81 | 15 | 801 | |
| Elena Bellan | 213 | 378 | 64 | 79 | 16 | 612 | |
| Kelly Scheu | 382 | 352 | 150 | 79 | 10 | 707 | |
| Veridiana Pires de Camargo | 519 | 622 | 65 | 201 | 26 | 843 | |
| Andrew W. Pippas | 625 | 313 | 76 | 92 | 10 | 713 | |
| Kirsten Leu | 376 | 432 | 97 | 136 | 13 | 629 | |
| Geraldine Goss | 439 | 482 | 136 | 139 | 24 | 791 |
All Works
Loading papers...